Open in Screener

ILMN

Illumina Inc

May 15 • 03:48PM ET

142.72

-0.52 -0.36 %

Healthcare • Diagnostics & Research • USA • Large • NASD

Peers: QGEN TXG PACB NTRA GH RVTY DHR TECH TMO BIO

| Held by: IJH VTI VB VBR VXF XMHQ MDY ARKK IBB SPMD

Index	-	P/E	25.90	EPS (ttm)	5.51	Insider Own	2.77%	Shs Outstand	152.00M	Perf Week	0.59%
Market Cap	21.59B	Forward P/E	24.12	EPS next Y	5.92	Insider Trans	-7.39%	Shs Float	147.12M	Perf Month	7.53%
Enterprise Value	22.98B	PEG	2.03	EPS next Q	1.23	Inst Own	104.87%	Short Float	4.45%	Perf Quarter	22.18%
Income	853.00M	P/S	4.92	EPS this Y	7.88%	Inst Trans	1.43%	Short Ratio	3.84	Perf Half Y	17.00%
Sales	4.39B	P/B	8.11	EPS next Y	13.31%	ROA	13.39%	Short Interest	6.55M	Perf YTD	8.81%
Book/sh	17.61	P/C	18.70	EPS next 5Y	11.89%	ROE	33.82%	52W High	155.53 -8.24%	Perf Year	76.42%
Cash/sh	7.63	P/FCF	22.17	EPS past 3/5Y	- 4.22%	ROIC	18.38%	52W Low	78.55 81.69%	Perf 3Y	-28.31%
Dividend Est.	-	EV/EBITDA	19.56	Sales past 3/5Y	-1.82% 6.02%	Gross Margin	67.14%	Volatility	4.43% 4.28%	Perf 5Y	-61.46%
Dividend TTM	-	EV/Sales	5.23	EPS Y/Y TTM	191.21%	Oper. Margin	20.59%	ATR (14)	5.85	Perf 10Y	7.26%
Dividend Ex-Date	-	Quick Ratio	1.36	Sales Y/Y TTM	1.25%	Profit Margin	19.43%	RSI (14)	60.82	Recom	2.22
Dividend Gr. 3/5Y	- -	Current Ratio	1.75	EPS Q/Q	5.61%	SMA20	5.42%	Beta	1.46	Target Price	143.83
Payout	0.00%	Debt/Eq	0.95	Sales Q/Q	4.80%	SMA50	10.66%	Rel Volume	0.75	Prev Close	143.24
Employees	8600	LT Debt/Eq	0.73	Earnings	Apr 30 AMC	SMA200	18.97%	Avg Volume	1.71M	Price	142.72
IPO	Jul 28, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.06% 1.66%	Trades		Volume	1,234,583	Change	-0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Resumed	RBC Capital Mkts	Outperform	$170
May-14-26	Upgrade	Daiwa Securities	Neutral → Outperform	$155
Aug-12-25	Downgrade	Daiwa Securities	Outperform → Neutral	$94
Jul-11-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$125
Mar-04-25	Reiterated	Citigroup	Neutral	$130 → $90
Feb-28-25	Downgrade	HSBC Securities	Buy → Hold	$100
Feb-10-25	Downgrade	Barclays	Equal Weight → Underweight	$130 → $100
Feb-07-25	Downgrade	TD Cowen	Buy → Hold	$177 → $140
Dec-11-24	Downgrade	Citigroup	Buy → Neutral	$190 → $165
Nov-12-24	Resumed	Morgan Stanley	Equal-Weight	$156
Oct-17-24	Upgrade	HSBC Securities	Hold → Buy	$180
Aug-28-24	Upgrade	Argus	Hold → Buy
Aug-16-24	Upgrade	Daiwa Securities	Neutral → Buy	$120 → $154
Aug-14-24	Upgrade	TD Cowen	Hold → Buy	$126 → $144
Aug-14-24	Upgrade	Barclays	Underweight → Equal Weight	$125
Jul-10-24	Upgrade	Citigroup	Neutral → Buy	$140
Jun-03-24	Resumed	Jefferies	Hold	$115
Jan-16-24	Downgrade	HSBC Securities	Buy → Hold
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$144
Dec-18-23	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$185

Show Previous Ratings

Today 09:45AM	Cisco upgraded, Doximity downgraded: Wall Street's top analyst calls (The Fly)
12:01AM	Nateras Stronghold in Cancer Recurrence Tests Prompts Woods Ark to Expand Stake (The Daily Upside)
May-11-26 03:34PM	Musk, Cook Expected to Join Trump for Xi Summit in China (Bloomberg)
May-06-26 09:31AM	Why The Dip In TEM Stock Is A Buying Window (Trefis)
May-01-26 08:30AM	Illumina, Inc. Q1 2026 Earnings Call Summary (Moby) +7.13%
03:17AM	Loading…
03:17AM	Illumina Inc (ILMN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... (GuruFocus.com)
Apr-30-26 04:36PM	Illumina: Q1 Earnings Snapshot (Associated Press) +5.29%
04:05PM	Illumina Reports Financial Results for First Quarter of Fiscal Year 2026 (PR Newswire)
Apr-16-26 09:15AM	DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows (PR Newswire)
Apr-14-26 09:15AM	Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease (PR Newswire)
Apr-09-26 04:30PM	Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026 (PR Newswire)
Apr-02-26 09:07AM	Illumina Announces Changes to Board of Directors (PR Newswire)
Mar-18-26 09:15AM	Illumina and Labcorp expand collaboration to broaden access to precision oncology testing (PR Newswire)
Mar-16-26 09:15AM	Illumina advances preventive genomics through strategic consortium with Veritas Genetics (PR Newswire)
Mar-09-26 09:50AM	Here's Why Illumina (ILMN) is a Strong Momentum Stock (Zacks)
09:40AM	Loading…
Mar-06-26 09:40AM	Here's Why Illumina (ILMN) is a Strong Value Stock (Zacks)
Mar-05-26 09:15AM	Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering (PR Newswire)
08:44AM	TEM's Diagnostics Arm Expanding Rapidly: What's Driving the Growth? (Zacks)
Mar-04-26 09:45AM	Why Illumina (ILMN) is a Top Growth Stock for the Long-Term (Zacks)
Mar-03-26 10:15AM	PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub (Zacks)
Mar-02-26 05:32PM	Quanterix Q4 Earnings Call Highlights (MarketBeat)
Feb-27-26 09:15AM	Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida (PR Newswire) +5.54%
Feb-26-26 10:48AM	TEM vs. ILMN: Which MedTech Stock Offers Greater Upside? (Zacks)
Feb-25-26 09:15AM	Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics (PR Newswire)
Feb-24-26 12:15PM	Illumina launches TruPath Genome, setting a new standard in genomic insight (PR Newswire)
Feb-23-26 09:15AM	Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility (PR Newswire)
Feb-20-26 04:26PM	This once-hot cancer-detection company's stock got cut in half after a failed trial (MarketWatch)
10:48AM	Genomics Stocks That Deserve a Place in Your Portfolio in 2026 (Zacks)
12:00AM	GRAIL Inc (GRAL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic Challenges (GuruFocus.com)
Feb-18-26 09:40AM	Why Illumina (ILMN) is a Top Value Stock for the Long-Term (Zacks)
06:02AM	Loading…
06:02AM	The Quality Screened Mid Cap XMHQ ETF Rocketed 283% And Made Money The Easy Way (24/7 Wall St.)
Feb-17-26 03:10PM	Illumina To Webcast Upcoming Investor Conference (PR Newswire)
Feb-12-26 10:00AM	Devyser Diagnostics AB (FRA:OL0) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
09:45AM	Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
08:24AM	Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips (Zacks)
12:36AM	5 Insightful Analyst Questions From Illumina's Q4 Earnings Call (StockStory)
Feb-09-26 11:19AM	Waters Q4 Earnings Call Highlights (MarketBeat)
09:15AM	Unlocking Illumina (ILMN) International Revenues: Trends, Surprises, and Prospects (Zacks)
Feb-06-26 01:25PM	Tech Bounces As Software Sell-Off Eases, Dow Jones Hits Records: What's Moving Markets Friday? (Benzinga) -10.40%
03:48AM	Analyst Report: Illumina, Inc. (Morningstar Research)
12:36AM	ILMN Q4 Deep Dive: Clinical Consumables Growth, Multiomics Expansion, and Margin Momentum (StockStory)
12:05AM	Illumina Inc (ILMN) Q4 2025 Earnings Call Highlights: Strong Clinical Growth Amidst Research ... (GuruFocus.com)
Feb-05-26 08:58PM	Illumina Q4 Earnings Call Highlights (MarketBeat)
07:00PM	Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:00PM	Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates (Zacks)
04:59PM	Illumina: Q4 Earnings Snapshot (Associated Press Finance)
04:17PM	Illumina (NASDAQ:ILMN) Reports Bullish Q4 CY2025 (StockStory)
04:06PM	Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 (PR Newswire)
Feb-04-26 09:15AM	Insights Into Illumina (ILMN) Q4: Wall Street Projections for Key Metrics (Zacks)
Feb-03-26 10:18PM	Illumina (ILMN) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory)
06:15PM	Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
09:15AM	Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo, supporting critical conservation genetics efforts globally (PR Newswire)
08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Feb-02-26 09:37AM	ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance (Zacks)
12:47AM	Grail files for FDA approval of multi-cancer early detection test (MedTech Dive)
Jan-30-26 10:00AM	Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:05AM	Illumina completes acquisition of SomaLogic (PR Newswire)
Jan-29-26 10:00AM	Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jan-27-26 08:55AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Jan-24-26 12:01PM	The Most Expensive Question Investors Ask (Barchart)
Jan-23-26 11:40AM	REGN or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
Jan-21-26 10:31PM	Life Sciences Tools & Services Stocks Q3 Teardown: Illumina (NASDAQ:ILMN) Vs The Rest (StockStory)
04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
Jan-20-26 01:19PM	Illumina Gets Medicare Boost for Cancer Test, Shares Climb (Benzinga)
09:15AM	Illumina secures CMS reimbursement for TruSight Oncology Comprehensive, expanding access to precision oncology (PR Newswire)
04:58AM	Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside (Insider Monkey)
12:05AM	Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning? (Benzinga)
Jan-16-26 02:22AM	The clinical candidates pharma execs are tracking (Pharma Voice)
Jan-15-26 08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jan-13-26 04:58PM	Illumina CEO Sees Big Growth Opportunity in China (Bloomberg)
01:01PM	JPM26: Illumina debuts Billion Cell Atlas to drive AI-driven drug discovery (Pharmaceutical Technology)
12:37PM	Analyst Report: Illumina, Inc. (Morningstar Research)
09:15AM	Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery (PR Newswire)
09:00AM	Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 (PR Newswire)
07:30AM	TEM's Collab for Oncology Patient Population Is Gaining Attention (Zacks)
Jan-12-26 04:07PM	Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026 (PR Newswire)
11:34AM	Nvidia, Eli Lilly announce $1 billion investment in AI drug discovery lab (Yahoo Finance)
08:09AM	Illumina's New Connected Multiomics Platform Set to Boost Its Stock (Zacks)
Jan-09-26 12:10PM	Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:55AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Jan-08-26 04:30PM	Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 (Business Wire)
04:30PM	Illumina Appoints Dr. Eric Green as Chief Medical Officer (PR Newswire)
Jan-07-26 11:40AM	REGN vs. ILMN: Which Stock Is the Better Value Option? (Zacks)
07:33AM	TEM's Stable Solvency and Financial Strength Are Gaining Attention (Zacks)
Jan-06-26 07:48PM	Analyst Report: Illumina, Inc. (Morningstar Research)
11:40AM	REGN vs. ILMN: Which Stock Should Value Investors Buy Now? (Zacks)
09:15AM	Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis (PR Newswire)
07:06AM	Three Genomics Stocks Worth Tracking This Year (Zacks)
Jan-02-26 07:35AM	Is This the Right Time to Add PBH Stock to Your Portfolio? (Zacks)
Dec-31-25 09:50AM	Here's Why Illumina (ILMN) is a Strong Momentum Stock (Zacks)
01:30AM	It's Earnings Warning Season. How to Profit From Others' Misery. (Barrons.com)
Dec-30-25 08:06AM	Should Myriad Genetics Stock Stay in Your Portfolio Right Now? (Zacks)
07:32AM	Should You Continue to Hold EXAS Stock in Your Portfolio Now? (Zacks)
Dec-26-25 07:49AM	Should You Continue to Hold BRKR Stock in Your Portfolio? (Zacks)
07:18AM	How Tempus AI Is Advancing Toward Regulatory Pricing Catch-Up (Zacks)
07:17AM	Reasons to Retain Penumbra Stock in Your Portfolio for Now (Zacks)
Dec-24-25 08:36AM	Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now? (Zacks)
Dec-23-25 02:08PM	Is This the Right Time to Add Veracyte Stock to Your Portfolio? (Zacks)
02:08PM	Abbott Stock May Benefit Following Volt PFA's FDA Approval (Zacks)
Dec-22-25 07:49AM	TMO Stock May Benefit From PPD CorEvitas Alzheimer's Registry Launch (Zacks)

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Meister Keith A.	Director	May 13 '26	Sale	145.55	225,067	32,759,594	3,604,441	May 14 07:21 PM
Meister Keith A.	Director	May 14 '26	Sale	145.34	104,393	15,172,381	3,500,048	May 14 07:21 PM
Corvex Management LP	Affiliate of Director (1)	May 13 '26	Proposed Sale	145.70	600,000	87,420,000		May 13 05:36 PM
Wedel Christensen Jakob	SVP, Strategy/Corp Development	May 06 '26	Sale	139.04	700	97,328	15,056	May 07 06:20 PM
JAKOB WEDEL	Officer	May 06 '26	Proposed Sale	139.04	700	97,328		May 06 04:10 PM
Davies Scott M	Chief Legal Officer	Feb 20 '26	Sale	116.18	1,336	155,216	16,334	Feb 24 04:11 PM
SCOTT DAVIES	Officer	Feb 20 '26	Proposed Sale	120.00	1,336	160,320		Feb 20 04:28 PM
Leckman Patricia	SVP, Chief People Officer	Feb 18 '26	Sale	116.18	2,370	275,347	16,321	Feb 18 04:49 PM
PATRICIA L LECKMAN	Officer	Feb 18 '26	Proposed Sale	116.18	2,370	275,347		Feb 18 04:22 PM
Barnard Steven	SVP, Chief Technology Officer	Feb 12 '26	Option Exercise	0.00	2,677	0	35,708	Feb 17 04:55 PM
Thaysen Jacob	Chief Executive Officer	Feb 12 '26	Option Exercise	0.00	13,264	0	95,353	Feb 17 04:53 PM
Pegels Kevin Carl	Chief of Global Operations	Feb 12 '26	Option Exercise	0.00	2,283	0	24,759	Feb 17 04:48 PM
Davies Scott M	Chief Legal Officer	Feb 12 '26	Option Exercise	0.00	1,370	0	19,257	Feb 17 04:46 PM
Leckman Patricia	SVP, Chief People Officer	Feb 12 '26	Option Exercise	0.00	1,028	0	20,419	Feb 17 04:45 PM
Ericksen Scott D	VP, Chief Accounting Officer	Feb 12 '26	Option Exercise	0.00	743	0	14,229	Feb 17 04:44 PM
Gottlieb Scott	Director	Feb 09 '26	Buy	117.81	200	23,562	12,723	Feb 11 04:04 PM
Davies Scott M	Chief Legal Officer	Dec 12 '25	Sale	136.09	323	43,957	17,887	Dec 16 05:00 PM
SCOTT DAVIES	Officer	Dec 12 '25	Proposed Sale	136.09	323	43,957		Dec 12 04:09 PM
Wedel Christensen Jakob	SVP, Strategy/Corp Development	Dec 08 '25	Sale	129.27	549	70,969	10,952	Dec 09 04:15 PM
JAKOB WEDEL	Officer	Dec 08 '25	Proposed Sale	129.27	549	70,969		Dec 08 04:31 PM
ILLUMINA, INC.	10% Owner	Nov 17 '25	Sale	79.85	1,000,000	79,850,000	3,502,126	Nov 18 09:33 PM
SCOTT DAVIES	Officer	Nov 12 '25	Proposed Sale	122.79	323	39,661		Nov 12 04:05 PM
Gottlieb Scott	Director	Nov 03 '25	Buy	122.13	500	61,065	12,523	Nov 05 04:05 PM

Open in Screener

TEM

Tempus AI Inc

May 15 • 03:48PM ET

44.24

-1.24 -2.72 %

Healthcare • Health Information Services • USA • Mid • NASD

Peers: EVH HCAT IQV VEEV NTRA CERT ILMN HQY RXRX SDGR

| Held by: ARKK VTI VB ARKG VBK VXF IBB IWP JTEK XOVR

Index	-	P/E	-	EPS (ttm)	-1.72	Insider Own	41.27%	Shs Outstand	174.18M	Perf Week	-11.27%
Market Cap	7.94B	Forward P/E	-	EPS next Y	-0.09	Insider Trans	-1.78%	Shs Float	105.45M	Perf Month	-18.70%
Enterprise Value	8.62B	PEG	-	EPS next Q	-0.14	Inst Own	55.15%	Short Float	25.38%	Perf Quarter	-14.84%
Income	-302.91M	P/S	5.82	EPS this Y	39.65%	Inst Trans	8.32%	Short Ratio	4.72	Perf Half Y	-37.77%
Sales	1.36B	P/B	19.04	EPS next Y	75.27%	ROA	-16.47%	Short Interest	26.76M	Perf YTD	-25.08%
Book/sh	2.32	P/C	12.43	EPS next 5Y	-	ROE	-81.58%	52W High	104.32 -57.59%	Perf Year	-29.33%
Cash/sh	3.56	P/FCF	-	EPS past 3/5Y	10.57% 1.21%	ROIC	-17.59%	52W Low	41.73 6.02%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	58.29% 46.57%	Gross Margin	62.22%	Volatility	4.87% 5.97%	Perf 5Y	-
Dividend TTM	-	EV/Sales	6.32	EPS Y/Y TTM	62.77%	Oper. Margin	-18.75%	ATR (14)	3.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.15	Sales Y/Y TTM	69.82%	Profit Margin	-22.20%	RSI (14)	35.65	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.31	EPS Q/Q	-77.97%	SMA20	-14.01%	Beta	3.68	Target Price	66.53
Payout	-	Debt/Eq	3.17	Sales Q/Q	36.12%	SMA50	-11.11%	Rel Volume	0.86	Prev Close	45.48
Employees	3800	LT Debt/Eq	3.14	Earnings	May 05 AMC	SMA200	-33.54%	Avg Volume	5.66M	Price	44.24
IPO	Jun 14, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	34.87% 0.77%	Trades		Volume	4,754,667	Change	-2.72%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-13-26	Upgrade	TD Cowen	Hold → Buy	$65
Apr-13-26	Initiated	Jefferies	Underperform	$35
Feb-19-26	Initiated	Mizuho	Outperform	$100
Feb-17-26	Initiated	Robert W. Baird	Outperform	$59
Dec-02-25	Resumed	Morgan Stanley	Overweight	$85
Oct-21-25	Downgrade	TD Cowen	Buy → Hold	$88
Oct-20-25	Initiated	Canaccord Genuity	Buy	$110
Sep-02-25	Initiated	H.C. Wainwright	Buy	$90
Apr-21-25	Initiated	BTIG Research	Buy	$60
Feb-25-25	Downgrade	JP Morgan	Overweight → Neutral	$50 → $55
Feb-12-25	Downgrade	William Blair	Outperform → Mkt Perform
Feb-05-25	Resumed	TD Cowen	Buy	$58 → $74
Dec-13-24	Initiated	Wolfe Research	Outperform	$60
Dec-09-24	Initiated	Guggenheim	Buy	$74
Nov-11-24	Downgrade	Stifel	Buy → Hold	$45 → $65
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral	$45 → $60
Aug-12-24	Initiated	Piper Sandler	Neutral	$40
Jul-09-24	Initiated	William Blair	Outperform
Jul-09-24	Initiated	TD Cowen	Buy	$50
Jul-09-24	Initiated	Stifel	Buy	$45

Show Previous Ratings

May-14-26 06:15PM	Imvivas CTA313 Lupus Drug Shows Promising Remission Results (Exec Edge)
08:30AM	Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience (Business Wire)
May-11-26 06:00AM	Ambry Genetics' CARE Program Wins 2026 MedTech Breakthrough Award for "Best Overall Health Informatics Solution" (Business Wire)
May-08-26 12:59AM	Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes (Business Wire)
May-07-26 07:11AM	Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense (Business Wire) -7.53%
09:31AM	Loading…
May-06-26 09:31AM	Why The Dip In TEM Stock Is A Buying Window (Trefis)
May-05-26 08:21PM	Tempus AI, Inc. Q1 2026 Earnings Call Summary (Moby)
04:01PM	Tempus Reports First Quarter 2026 Results (Business Wire)
Apr-29-26 08:30AM	Tempus to Host Inaugural Investor Day on May 29, 2026 (Business Wire)
Apr-28-26 08:30AM	Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026 (Business Wire)
Apr-23-26 08:30AM	Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine (Business Wire) -7.33%
Apr-21-26 08:30AM	Tempus to Report First Quarter 2026 Financial Results on May 5 (Business Wire)
Apr-15-26 08:30AM	Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring (Business Wire) +13.89%
Apr-14-26 08:30AM	Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026 (Business Wire) +7.72%
Apr-13-26 09:58AM	Nike downgraded, Starbucks upgraded: Wall Street's top analyst calls (The Fly) +7.08%
08:30AM	Loading…
08:30AM	Tempus Launches Automated "Active Follow-Up" Service to Support Guideline-Concordant Care (Business Wire)
Apr-09-26 08:30AM	Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE (Business Wire) -7.03%
Apr-08-26 04:01PM	Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-26-26 08:57AM	Cathie Wood's Ark Dumped More Meta Stock-and Loaded Up on Another AI Stock Instead (Barrons.com)
06:34AM	Daiichi Sankyo and Tempus AI collaborate on ADC clinical development (Pharmaceutical Business Review)
04:36AM	Meta Stock Dumped by Cathie Wood. Her ARK Funds Go Big On This AI Play Instead. (Barrons.com)
Mar-24-26 03:01PM	Tongcheng Travel Holdings Ltd (FRA:TEM) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Mar-17-26 08:30AM	Tempus and Blood Cancer United Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries (Business Wire)
Mar-11-26 08:30AM	Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings (Business Wire)
Mar-10-26 01:33PM	Hims and Hers Expands Consumer-Focused Digital Health Platform (Zacks)
Mar-09-26 08:52AM	Should You Buy, Hold or Sell Tempus AI Stock Heading Into 2026? (Zacks)
Mar-07-26 07:11AM	Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine (Insider Monkey)
Mar-05-26 08:44AM	TEM's Diagnostics Arm Expanding Rapidly: What's Driving the Growth? (Zacks)
Mar-04-26 06:00PM	Is Tempus AI, Inc. (TEM) A Good Stock To Buy Now? (Insider Monkey)
Mar-03-26 02:33PM	AI-Powered Tempus Inks New Multi-Year Merck Deal (Benzinga)
12:19PM	Loading…
12:19PM	Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes (PR Newswire)
08:30AM	Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine (Business Wire)
Mar-01-26 08:00AM	Consumer Tech News (Feb 23-27): US-Taiwan Trade Tensions Escalates, Amazon Invests $12B In US & More (Benzinga)
Feb-26-26 10:48AM	TEM vs. ILMN: Which MedTech Stock Offers Greater Upside? (Zacks)
08:30AM	Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference (Business Wire)
Feb-25-26 09:20PM	Cathie Wood Is Buying The Tempus AI Dip, Ark Snaps Up Stock Worth $11 Million (Benzinga) -7.32%
09:44AM	Tempus AI Posts 83% Revenue Growth Yet Stumbles on Full Year Profitability Target (24/7 Wall St.)
08:30AM	Tempus AI, Inc. Q4 2025 Earnings Call Summary (Moby)
07:26AM	TEM Q4 Earnings Miss, Revenues Beat, Stock Down in After-Market (Zacks)
01:07AM	Tempus AI Q4 Earnings Call Highlights (MarketBeat)
12:02AM	Tempus AI Inc (TEM) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
Feb-24-26 08:19PM	AMD, Zeta Global, MercadoLibre, Tempus AI And Workday: Why These 5 Stocks Are On Investors' Radars Today (Benzinga)
07:30PM	Tempus AI (TEM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
05:32PM	Tempus AI Stock Drops Despite Q4 Earnings Beat: Details (Benzinga)
04:01PM	Tempus Reports Fourth Quarter and Full Year 2025 Results (Business Wire)
Feb-23-26 10:33AM	Nvidia, Joby, CoreWeave, Lucid and More Stocks with Earnings This Week (Benzinga)
07:46AM	AppLovin Surges 11% While Tempus AI and Micron Also Outpace Most AI Stocks (24/7 Wall St.)
07:21AM	Here's How Tempus AI Is Tapping the Imagining Space (Zacks)
Feb-22-26 08:30AM	Consumer Tech News (Feb 16-20): Big Techs To Boost AI in India, EV Policy Shifts & More (Benzinga)
Feb-20-26 10:55AM	Hims & Hers Accelerates AI Preventive Care and Platform Strategy (Zacks)
09:04AM	AI-Driven Innovation Accelerates Tempus AI's Expansion Across MedTech (Zacks)
Feb-19-26 03:19PM	2 Tech Bets Cathie Wood is Quietly Trimming Right Now: Should You Too? (Barchart) +6.77%
02:01PM	Tempus Shares Jump On AI Cancer Tool (GuruFocus.com)
12:04PM	Tempus AI Stock Jumps As Mizuho Starts Coverage, Earnings Scheduled For Next Week (Benzinga)
09:40AM	Shopify, eBay upgraded: Wall Street's top analyst calls (The Fly)
09:15AM	Unlocking Q4 Potential of Tempus (TEM): Exploring Wall Street Estimates for Key Metrics (Zacks)
08:09AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Analog Devices, Chewy, Credo Technology, eBay, Fiverr, Shopify, Verizon, and More (24/7 Wall St.)
Feb-18-26 11:52AM	Why Tempus AI Stock Is Up Today And What to Watch Before Next Weeks Earnings (24/7 Wall St.) +6.85%
11:12AM	What's Going On With Tempus AI Stock Today? (Benzinga)
09:41AM	Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy? (Zacks)
08:30AM	Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm (Business Wire)
Feb-17-26 04:44PM	Cathie Wood Adds 210K Shares to a Rising AI Bet With Upside of 102% (Barchart)
11:32AM	Market Movers: Citi Bullish on NVDA Heading into Earnings (24/7 Wall St.)
11:20AM	Tempus AI & Median Partner to Add AI Lung Cancer Screening to Pixel (Zacks)
09:43AM	Dollar General downgraded, Dollar Tree upgraded: Wall Street's top analyst calls (The Fly)
07:49AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Albemarle, BitGo Holdings, Chevron, Dollar General, Equifax, Shopify, Southwest Airlines, Visa, and More (24/7 Wall St.)
Feb-13-26 09:33AM	Should You Buy, Hold or Sell Tempus AI Stock Pre-Q4 Earnings Release? (Zacks)
Feb-12-26 09:22PM	Cathie Wood's Ark Scoops Up $12.4 Million In Beaten-Down Robinhood - Dumps More Airbnb Shares (Benzinga) -5.28%
04:05PM	Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform (Business Wire)
04:05PM	Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis LCS Software as a Medical Device in the United States (Business Wire)
Feb-11-26 11:13AM	HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell? (Zacks)
Feb-10-26 09:54AM	Jim Cramer on Tempus (TEM): "It's Going to Go Back Down Again" (Insider Monkey)
08:30AM	Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24 (Business Wire)
Feb-04-26 10:17PM	Tempus AI, Inc. (TEM): A Bull Case Theory (Insider Monkey)
07:00AM	Ambry's Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes (Business Wire)
Feb-02-26 07:00AM	Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield (Business Wire)
Feb-01-26 06:50PM	Here Are Congresswoman Nancy Pelosi's Initial Stock Moves in 2026: They Include Nvidia, Alphabet, and Amazon Stocks, and Others (Motley Fool)
08:30AM	Tempus AI, Inc. (TEM) Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones (Insider Monkey)
Jan-29-26 09:25AM	AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift (PR Newswire)
08:47AM	TEM vs. DOCS: Which Medical-Tech Stock Looks Promising Amid AI Boom? (Zacks)
Jan-27-26 11:09AM	Nancy Pelosi Just Doubled Down on AI Again (24/7 Wall St.)
08:30AM	Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers (Business Wire)
Jan-26-26 08:56PM	Cathie Wood Bets Big On AI Trifecta: Ark Deploys $1.4 Million Across Medical, Autonomous Driving Sectors (Benzinga)
06:18PM	Pelosi's Bullish 2026 Buy List: AI, Power & Dividends (MarketBeat)
02:21PM	Nancy Pelosi Discloses New Stock Trades: Here's What She's Loading Up On - And What's She's Selling (Benzinga)
01:26PM	Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday? (Benzinga)
10:20AM	Hims & Hers Scales Platform-Led Digital Healthcare Access and Care (Zacks)
09:40AM	How TEM Is Capitalizing on AI-Driven Pathology Market Growth (Zacks)
Jan-22-26 09:06PM	Cathie Wood Loads Up On This Robotaxi Stock, Ark Dumps Roku In Latest Trades (Benzinga)
12:42PM	HIMS vs. TEM: Which Health-Tech Stock Looks More Compelling? (Zacks)
10:10AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Jan-21-26 09:06PM	Cathie Wood Doubles Down On Netflix Despite Weak Guidance, Ark Invest Dumps This Social Media Stock (Benzinga)
04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
08:30AM	Tempus Announces the Launch of Paige Predict (Business Wire)
07:57AM	Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention (Zacks)
Jan-20-26 12:05AM	Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning? (Benzinga) -5.05%
Jan-13-26 07:48AM	Tempus AI (TEM) Soars 15% on $1.1-Billion Deal (Insider Monkey)
07:30AM	TEM's Collab for Oncology Patient Population Is Gaining Attention (Zacks)
Jan-12-26 07:27PM	Why Tempus AI Stock Rose Today (Motley Fool)
04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily)

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEFKOFSKY ERIC P	CEO and Chairman	Apr 28 '26	Sale	51.13	166,250	8,500,623	8,841,783	Apr 30 04:30 PM
Eric Lefkofsky	Officer	Apr 28 '26	Proposed Sale	52.68	166,250	8,758,050		Apr 28 04:41 PM
JENNIFER DOUDNA	Director	Apr 15 '26	Proposed Sale	49.53	3,348	165,826		Apr 15 04:39 PM
LEFKOFSKY ERIC P	CEO and Chairman	Mar 26 '26	Sale	46.38	166,250	7,711,150	8,875,033	Mar 27 09:46 PM
Eric Lefkofsky	Officer	Mar 26 '26	Proposed Sale	46.76	166,250	7,773,850		Mar 26 04:27 PM
Epstein David R	Director	Mar 02 '26	Sale	50.69	250	12,672	25,801	Mar 04 04:30 PM
Rogers James William	Chief Financial Officer	Mar 02 '26	Sale	50.69	11,414	578,576	127,248	Mar 04 04:30 PM
JAMES ROGERS	Officer	Mar 02 '26	Proposed Sale	53.25	13,583	723,295		Mar 02 04:40 PM
DAVID R. EPSTEIN	Director	Mar 02 '26	Proposed Sale	53.25	870	46,328		Mar 02 04:38 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 19 '26	Sale	58.87	166,250	9,787,605	8,908,283	Feb 20 09:45 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 19 '26	Sale	59.05	13,587	802,312	1,989,626	Feb 20 09:45 PM
Phelps Erik	EVP, Chief Admin. Officer	Feb 19 '26	Sale	59.43	9,464	562,472	79,816	Feb 20 06:45 PM
Bartolucci Ryan M	Chief Accounting Officer	Feb 19 '26	Sale	59.05	2,902	171,363	41,159	Feb 20 06:45 PM
Polovin Andrew	EVP, Chief Legal Officer	Feb 20 '26	Sale	60.31	10,949	660,292	126,918	Feb 20 06:45 PM
Polovin Andrew	EVP, Chief Legal Officer	Feb 19 '26	Sale	59.05	8,143	480,844	99,447	Feb 20 06:45 PM
Fukushima Ryan	Chief Executive Officer, Data	Feb 19 '26	Sale	59.05	9,592	566,408	694,354	Feb 20 06:45 PM
Rogers James William	Chief Financial Officer	Feb 19 '26	Sale	59.05	10,084	595,460	101,166	Feb 20 06:45 PM
ERIK PHELPS	Officer	Feb 20 '26	Proposed Sale	59.96	3,823	229,227		Feb 20 04:28 PM
ANDREW POLOVIN	Officer	Feb 20 '26	Proposed Sale	59.96	10,949	656,502		Feb 20 04:25 PM
Ryan M. Bartolucci	Officer	Feb 19 '26	Proposed Sale	56.16	2,902	162,976		Feb 19 09:24 PM
Andrew Polovin	Officer	Feb 19 '26	Proposed Sale	56.16	8,143	457,311		Feb 19 09:22 PM
Eric Paul Lefkofsky	Officer	Feb 19 '26	Proposed Sale	56.16	13,587	763,046		Feb 19 09:20 PM
Ryan Fukushima	Officer	Feb 19 '26	Proposed Sale	56.16	9,592	538,687		Feb 19 09:17 PM
Erik Phelps	Officer	Feb 19 '26	Proposed Sale	56.16	5,650	317,304		Feb 19 09:15 PM
James William Rogers	Officer	Feb 19 '26	Proposed Sale	56.16	10,084	566,317		Feb 19 09:13 PM
ERIK PHELPS	Officer	Feb 19 '26	Proposed Sale	56.16	3,814	214,194		Feb 19 04:43 PM
Eric Lefkofsky	Officer	Feb 19 '26	Proposed Sale	56.16	166,250	9,336,600		Feb 19 04:08 PM
Tempus AI, Inc.	10% Owner	Nov 18 '25	Buy	7.67	64,750	496,632	12,783,550	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 25 '25	Buy	10.62	23,600	250,665	12,918,346	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 22 '25	Buy	8.93	28,000	250,040	13,039,067	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 21 '25	Buy	9.40	26,499	249,190	12,869,521	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 24 '25	Buy	9.87	25,225	248,971	12,894,746	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 19 '25	Buy	8.12	30,645	248,837	12,814,195	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 20 '25	Buy	8.63	28,827	248,777	12,843,022	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 17 '25	Buy	7.86	31,650	248,769	12,949,996	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 19 '25	Buy	8.39	29,641	248,688	13,011,067	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 18 '25	Buy	7.91	31,430	248,611	12,981,426	Feb 13 05:24 PM
Epstein David R	Director	Feb 02 '26	Sale	59.41	370	21,982	26,051	Feb 04 04:30 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jan 28 '26	Sale	65.56	166,250	10,899,207	8,941,533	Jan 30 04:15 PM
Eric Lefkofsky	Officer	Jan 28 '26	Proposed Sale	66.81	166,250	11,107,162		Jan 28 04:21 PM
Fukushima Ryan	Chief Operating Officer	Jan 05 '26	Sale	64.26	5,000	321,300	148,808	Jan 07 06:25 PM
Doudna Jennifer A	Director	Jan 02 '26	Sale	60.17	1,250	75,212	22,702	Jan 06 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Dec 18 '25	Sale	63.99	166,250	10,638,478	8,974,783	Dec 22 05:41 PM
Eric Lefkofsky	Officer	Dec 18 '25	Proposed Sale	64.61	166,250	10,741,413		Dec 18 04:39 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Dec 16 '25	Sale	67.42	1,302	87,781	89,280	Dec 18 04:15 PM
ERIK PHELPS	Officer	Dec 16 '25	Proposed Sale	68.67	1,302	89,408		Dec 16 04:29 PM
Rogers James William	Chief Financial Officer	Dec 11 '25	Sale	73.20	19,966	1,461,479	111,250	Dec 12 04:30 PM
JAMES ROGERS	Officer	Dec 11 '25	Proposed Sale	75.07	19,966	1,498,848		Dec 11 04:23 PM
Frederick Wayne A.I.	Director	Dec 05 '25	Sale	77.23	3,675	283,820	24,836	Dec 09 04:15 PM
WAYNE FREDERICK	Director	Dec 05 '25	Proposed Sale	77.23	3,675	283,802		Dec 05 04:15 PM
Epstein David R	Director	Dec 01 '25	Sale	75.55	250	18,888	26,421	Dec 03 04:50 PM
Fukushima Ryan	Chief Operating Officer	Dec 01 '25	Sale	75.72	5,000	378,620	153,808	Dec 03 04:50 PM
Doudna Jennifer A	Director	Dec 01 '25	Sale	75.55	676	51,072	23,952	Dec 03 04:50 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 24 '25	Sale	74.10	166,250	12,319,125	9,008,033	Nov 25 04:30 PM
Polovin Andrew	EVP and General Counsel	Nov 24 '25	Sale	75.00	12,874	965,550	107,590	Nov 25 04:30 PM
Eric Lefkofsky	Officer	Nov 20 '25	Proposed Sale	70.40	166,250	11,703,285		Nov 24 06:11 PM
ANDREW POLOVIN	Officer	Nov 24 '25	Proposed Sale	70.29	12,874	904,913		Nov 24 04:29 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 20 '25	Sale	68.97	166,250	11,466,099	9,041,283	Nov 20 07:56 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 18 '25	Sale	65.54	16,829	1,102,944	2,003,213	Nov 20 07:56 PM
Rogers James William	Chief Financial Officer	Nov 18 '25	Sale	65.54	7,257	475,611	131,216	Nov 20 07:05 PM
Polovin Andrew	EVP and General Counsel	Nov 19 '25	Sale	68.06	6,387	434,707	120,464	Nov 20 07:05 PM
Polovin Andrew	EVP and General Counsel	Nov 18 '25	Sale	65.54	5,205	341,126	126,851	Nov 20 07:05 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Nov 18 '25	Sale	65.54	3,533	231,547	90,582	Nov 20 07:05 PM
Fukushima Ryan	Chief Operating Officer	Nov 18 '25	Sale	65.54	10,099	661,870	829,081	Nov 20 07:05 PM
Bartolucci Ryan M	Chief Accounting Officer	Nov 18 '25	Sale	65.54	1,834	120,197	44,061	Nov 20 07:05 PM
Eric Lefkofsky	Officer	Nov 20 '25	Proposed Sale	69.09	166,250	11,486,212		Nov 20 04:46 PM
ANDREW POLOVIN	Officer	Nov 19 '25	Proposed Sale	66.77	6,387	426,460		Nov 19 04:22 PM
Ryan M. Bartolucci	Officer	Nov 18 '25	Proposed Sale	66.39	1,834	121,759		Nov 18 07:09 PM
Ryan Fukushima	Officer	Nov 18 '25	Proposed Sale	66.39	10,099	670,473		Nov 18 07:08 PM
Eric Paul Lefkofsky	Officer	Nov 18 '25	Proposed Sale	66.39	16,829	1,117,277		Nov 18 07:07 PM
Andrew Polovin	Officer	Nov 18 '25	Proposed Sale	66.39	5,205	345,560		Nov 18 07:05 PM
James William Rogers	Officer	Nov 18 '25	Proposed Sale	66.39	7,257	481,792		Nov 18 07:04 PM
Erik Phelps	Officer	Nov 18 '25	Proposed Sale	66.39	3,533	234,556		Nov 18 07:03 PM
Doudna Jennifer A	Director	Nov 11 '25	Sale	71.45	1,926	137,613	24,628	Nov 13 04:15 PM
JENNIFER DOUDNA	Director	Nov 11 '25	Proposed Sale	71.78	3,852	276,497		Nov 12 07:03 AM
Fukushima Ryan	Chief Operating Officer	Nov 03 '25	Sale	89.03	5,000	445,160	125,000	Nov 05 04:15 PM
Epstein David R	Director	Nov 03 '25	Sale	90.00	370	33,300	26,671	Nov 05 04:15 PM
VANESSA L KUBO	Officer	Nov 03 '25	Proposed Sale	89.85	20,000	1,797,000		Nov 03 04:26 PM
DAVID R. EPSTEIN	Director	Nov 03 '25	Proposed Sale	89.85	990	88,952		Nov 03 04:25 PM
LEFKOFSKY ERIC P	CEO and Chairman	Oct 28 '25	Sale	89.11	332,500	29,629,006	9,074,532	Oct 30 04:31 PM
Eric Lefkofsky	Officer	Oct 28 '25	Proposed Sale	91.58	332,500	30,450,350		Oct 28 04:09 PM
Fukushima Ryan	Chief Operating Officer	Oct 06 '25	Sale	92.32	5,000	461,606	130,000	Oct 08 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Sep 25 '25	Sale	76.56	332,500	25,457,014	9,141,032	Sep 29 04:33 PM
Eric Lefkofsky	Officer	Sep 25 '25	Proposed Sale	84.13	332,500	27,973,225		Sep 25 07:04 PM
Fukushima Ryan	Chief Operating Officer	Sep 02 '25	Sale	75.80	10,000	758,028	135,000	Sep 04 04:15 PM
Epstein David R	Director	Sep 02 '25	Sale	73.64	250	18,410	27,041	Sep 04 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 27 '25	Sale	74.10	332,500	24,637,581	9,207,533	Aug 29 05:13 PM
Leonsis Theodore	Director	Aug 26 '25	Sale	75.83	20,000	1,516,600	66,756	Aug 28 04:15 PM
Eric Lefkofsky	Officer	Aug 27 '25	Proposed Sale	75.90	332,500	25,236,750		Aug 27 04:19 PM
Leonsis Theodore	Director	Aug 26 '25	Proposed Sale	75.83	20,000	1,516,650		Aug 26 01:27 PM
Polovin Andrew	EVP and General Counsel	Aug 19 '25	Sale	74.65	5,398	402,982	132,056	Aug 21 04:15 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Aug 19 '25	Sale	74.65	3,664	273,532	94,115	Aug 21 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 19 '25	Sale	74.65	17,458	1,303,307	2,020,042	Aug 21 04:15 PM
Fukushima Ryan	Chief Operating Officer	Aug 19 '25	Sale	74.65	17,460	1,303,456	839,180	Aug 21 04:15 PM
Rogers James William	Chief Financial Officer	Aug 19 '25	Sale	74.65	7,528	561,994	138,473	Aug 21 04:15 PM
Bartolucci Ryan M	Chief Accounting Officer	Aug 19 '25	Sale	74.65	1,904	142,141	45,895	Aug 21 04:15 PM
Erik Phelps	Officer	Aug 19 '25	Proposed Sale	78.45	3,664	287,441		Aug 20 07:19 AM
Andrew Polovin	Officer	Aug 19 '25	Proposed Sale	78.45	5,398	423,473		Aug 20 07:17 AM
Ryan Fukushima	Officer	Aug 19 '25	Proposed Sale	78.45	17,460	1,369,737		Aug 20 07:15 AM
Eric Paul Lefkofsky	Officer	Aug 19 '25	Proposed Sale	78.45	17,458	1,369,580		Aug 20 07:14 AM

Open in Screener

PFE

Pfizer Inc

May 15 • 03:48PM ET

25.26

-0.49 -1.90 %

Healthcare • Drug Manufacturers - General • USA • Large • NYSE

Peers: BMY SNY AZN MRK GSK ABBV TAK JNJ AMGN LLY

| Held by: VTI VOO IVV SPY VTV XLV VYM DVY VHT FDL

Index	S&P 500	P/E	19.37	EPS (ttm)	1.30	Insider Own	0.06%	Shs Outstand	5.70B	Perf Week	-1.64%
Market Cap	143.97B	Forward P/E	8.89	EPS next Y	2.84	Insider Trans	0.00%	Shs Float	5.70B	Perf Month	-7.20%
Enterprise Value	195.65B	PEG	-	EPS next Q	0.68	Inst Own	68.50%	Short Float	2.46%	Perf Quarter	-8.41%
Income	7.46B	P/S	2.27	EPS this Y	-7.92%	Inst Trans	1.49%	Short Ratio	3.72	Perf Half Y	-2.36%
Sales	63.31B	P/B	1.60	EPS next Y	-4.17%	ROA	3.60%	Short Interest	140.32M	Perf YTD	1.45%
Book/sh	15.81	P/C	11.01	EPS next 5Y	-8.84%	ROE	8.29%	52W High	28.75 -12.12%	Perf Year	11.77%
Cash/sh	2.29	P/FCF	15.18	EPS past 3/5Y	-37.19% -3.57%	ROIC	4.95%	52W Low	22.09 14.35%	Perf 3Y	-32.02%
Dividend Est.	1.75 (6.94%)	EV/EBITDA	8.24	Sales past 3/5Y	-14.56% 8.48%	Gross Margin	65.16%	Volatility	1.77% 1.99%	Perf 5Y	-36.88%
Dividend TTM	1.72 (6.81%)	EV/Sales	3.09	EPS Y/Y TTM	-5.39%	Oper. Margin	27.08%	ATR (14)	0.55	Perf 10Y	-19.69%
Dividend Ex-Date	May 08, 2026	Quick Ratio	0.94	Sales Y/Y TTM	1.36%	Profit Margin	11.79%	RSI (14)	32.56	Recom	2.57
Dividend Gr. 3/5Y	2.23% 2.37%	Current Ratio	1.25	EPS Q/Q	-9.78%	SMA20	-4.31%	Beta	0.30	Target Price	28.88
Payout	126.85%	Debt/Eq	0.72	Sales Q/Q	5.37%	SMA50	-6.22%	Rel Volume	0.77	Prev Close	25.75
Employees	75000	LT Debt/Eq	0.67	Earnings	May 05 BMO	SMA200	-1.92%	Avg Volume	37.73M	Price	25.26
IPO	Jan 17, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.92% 4.41%	Trades		Volume	28,363,422	Change	-1.90%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-02-26	Upgrade	Argus	Hold → Buy	$35
Feb-25-26	Initiated	RBC Capital Mkts	Underperform	$25
Feb-20-26	Initiated	Barclays	Underweight	$25
Feb-12-26	Downgrade	Daiwa Securities	Outperform → Neutral	$27
Jan-07-26	Resumed	UBS	Neutral	$25
Dec-02-25	Resumed	Citigroup	Neutral	$26
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$30
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$24
Dec-10-24	Resumed	BofA Securities	Neutral	$29
Nov-15-24	Initiated	Wolfe Research	Underperform	$25
Oct-25-24	Resumed	Citigroup	Neutral	$30
Oct-17-24	Initiated	Bernstein	Mkt Perform	$32
Aug-07-24	Upgrade	Daiwa Securities	Neutral → Outperform
Mar-22-24	Downgrade	Argus	Buy → Hold
Feb-23-24	Initiated	Guggenheim	Buy	$36
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$32
Oct-20-23	Resumed	UBS	Neutral	$36 → $34
Oct-16-23	Upgrade	Jefferies	Hold → Buy	$38 → $39
Jul-17-23	Reiterated	JP Morgan	Neutral	$45 → $41
Jul-14-23	Initiated	HSBC Securities	Buy	$50

Show Previous Ratings

May-14-26 08:34PM	Pfizer receives EC approval for Hympavzi to treat haemophilia (Pharmaceutical Business Review)
02:22PM	Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch (Barrons.com)
May-13-26 08:34PM	Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary (Moby)
06:45AM	European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors (Business Wire)
May-12-26 08:05AM	Arvinas, Pfizer find new partner for Protac breast cancer drug (BioPharma Dive)
07:39AM	Loading…
07:39AM	BridgeBios Attruby challenges Pfizers Vyndamax legacy in pivotal ATTR trial (Pharmaceutical Technology)
05:11AM	How tough is it getting for vaccine makers in the U.S.? (Pharma Voice)
May-08-26 01:50PM	Nasdaq, S&P 500 Enjoy Another Record-Breaking Week (Schaeffer's Research)
11:42AM	GLP-1 battle heats up between Eli Lilly and Novo Nordisk (Yahoo Finance Video)
May-06-26 02:06PM	Pfizer CEO Backs Trump's CDC Pick After Vaccine Policy Upheaval (GuruFocus.com)
09:15AM	Can Pfizer Stock Outrun A $17B Revenue Void? (Trefis)
03:00AM	CellCentric raises $220M for a transformative multiple myeloma medicine (BioPharma Dive)
May-05-26 04:54PM	Pfizer Inc. Q1 2026 Earnings Call Summary (Moby)
03:56PM	Pfizer CEO Says Digging Out of Post-Covid Hole Will Take a Few More Years (The Wall Street Journal)
02:41PM	Pfizer Beats Sales Estimates As $17 Billion Patent Cliff Looms (GuruFocus.com)
01:30PM	Loading…
01:30PM	Pfizer pins post 2028 return to growth on new obesity and cancer drugs (Reuters)
12:41PM	Pfizer beats Q1 revenue and profit estimates, reaffirms 2026 guidance (Proactive)
12:30PM	Chicken or the Egg? Why We Need to Rethink Data and Funding in Startups (Entrepreneur)
11:05AM	Pfizer tops Q1 expectations on growth from newer products (InvestorsHub)
10:44AM	2 Trendlines in Focus For Pfizer Stock After Earnings (Schaeffer's Research)
09:54AM	BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. (Barrons.com)
09:02AM	Stock Futures Higher on Cooling Oil, Upbeat Earnings (Schaeffer's Research)
08:53AM	Why Pfizer's 'Mild' First-Quarter Report Likely Won't Satisfy Skeptics (Investor's Business Daily)
08:45AM	Pfizer Q1 2026 earnings beat estimates on newer drug growth (Quartz)
08:35AM	Pfizer Posts Better-Than-Expected Revenue, Profit (The Wall Street Journal)
08:00AM	How Pfizers CEO says he uses AI to make decisions (CNN Business)
07:34AM	Pfizer beats first quarter estimates on strong product growth (Investing.com)
07:23AM	Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending (The Wall Street Journal)
07:06AM	Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates (Barrons.com)
06:54AM	Pfizer: Q1 Earnings Snapshot (Associated Press)
06:45AM	Loading…
06:45AM	Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance (Business Wire)
04:59AM	AMD headlines Tuesday's earnings slate (MarketWatch)
May-04-26 07:55PM	Review & Preview: War Redux (Barrons.com)
07:00PM	AMD and Pfizer earnings, job openings, Fedspeak: What to Watch (Yahoo Finance Video)
05:06AM	Protein degraders gain speed as Arvinas scores landmark approval (Pharma Voice)
May-01-26 10:50AM	Eli Lilly Stocks Path To 30% Upside (Trefis)
07:30AM	Eli Lilly: The Most Expensive Stock in Pharma; and Maybe the Best (GuruFocus.com)
Apr-30-26 01:00PM	The Week Ahead: Employment Data, Fed Speeches (Schaeffer's Research)
12:08PM	Thinning revenues: inside the $14bn Eliquis patent cliff (Pharmaceutical Technology)
11:41AM	Bristol Myers beats quarterly profit estimates on blood thinner, cancer drug sales (Reuters)
Apr-29-26 12:59PM	Pfizer protects $6.4bn heart disease blockbuster from generics, for now (Pharmaceutical Technology)
07:21AM	FDA tests out real-time clinical trials; AbbVie closes in on a KRAS biotech (BioPharma Dive)
06:45AM	Pfizers ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma (Business Wire)
03:09AM	OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ... (GuruFocus.com)
02:58AM	AWS CEO Matt Garman sees huge business opportunity for Amazon in AI-powered software: Everything is going to be remade (Fortune)
Apr-28-26 10:17AM	Pfizer Reaches Three Settlement Agreements for VYNDAMAX (Business Wire)
08:28AM	Pfizer deals extend patent life for a top-selling rare disease drug (BioPharma Dive)
Apr-24-26 04:55PM	CureVac sues Moderna for patent infringement over COVID-19 vaccines (Reuters)
01:34PM	Bristol Myers, Pfizer Bring Eliquis to Cost Plus at $345 Monthly (GuruFocus.com)
11:00AM	Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims (Yahoo Finance Video)
06:59AM	Bristol Myers Squibb and Pfizer to Make Eliquis (apixaban) Available via Mark Cuban Cost Plus Drug Company (Business Wire)
Apr-23-26 05:49PM	Regeneron Shares Up on Trump Drug Pricing Deal (Barrons.com)
02:27AM	Richest countries in 2026: New measure of wealth pushes France and Germany out of top ten (Euronews)
Apr-22-26 04:45PM	Pfizer Declares Second-Quarter 2026 Dividend (Business Wire)
11:01AM	Pfizer CFO Dave Denton on Oncology, Obesity, and Pfizers Next Growth Cycle (NYSE)
Apr-21-26 12:23PM	Eli Lilly eyes Kelonia Therapeutics in $7B deal with $3.25B to be paid up front. How to invest early to grow your wealth (Moneywise)
11:51AM	Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026 (Business Wire)
06:29AM	Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy (Pharmaceutical Business Review)
Apr-20-26 10:47AM	Novo's Once-Daily Sickle Cell Pill Hits Milestone. A Smaller Rival Is Sinking 24%. (Barrons.com)
06:45AM	U.S. FDA Grants Priority Review to sBLA for PADCEV + Keytruda as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility (PR Newswire)
Apr-17-26 04:13PM	Why Is Abbott Stock Trending Lower? (Trefis)
Apr-13-26 11:43AM	How Eli Lilly Stock Rises To $2,000 (Trefis)
Apr-11-26 08:01PM	How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results (Quartz)
Apr-10-26 08:11PM	Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing (Quartz)
Apr-09-26 10:00AM	Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders (Business Wire)
Apr-08-26 12:44PM	Gilead Agrees $5 Billion Tubulis Acquisition To Expand Cancer Drug Pipeline (GuruFocus.com)
Apr-07-26 05:47PM	The $190 Billion 'Diabesity' Market Is Set to Explode. Lilly and Novo Face These Stock Catalysts. (Barrons.com)
Apr-02-26 04:05PM	Trump slaps steep tariffs on patented drug imports (Supply Chain Dive)
11:37AM	Boost Pfizer's Already Hefty 6% Dividend Yield With A Covered Call (Investor's Business Daily)
08:01AM	JNJ Stocks 60% Breakout: Why Wall Street is Torn (Trefis)
Apr-01-26 04:07PM	Why 2026 Is Biotech's Comeback Year (Barrons.com)
04:05PM	Oric Shares Fall 40% as Cancer-Drug Data Falls Short of Expectations (The Wall Street Journal)
10:02AM	Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer - And Plunges (Investor's Business Daily)
09:30AM	Pfizer Pulls Back From South San Francisco (GuruFocus.com)
04:00AM	Will Pfizers Lyme disease gamble pay off or set the space back? (Pharma Voice)
Mar-31-26 03:45PM	$2 Billion Bayer Verdict: What the Roundup Decision Means for MAHA (Exec Edge)
Mar-30-26 10:44AM	Pharma Stocks Pfizer, GSK Offer Defensive Plays in an Uncertain Market: Charts (Barrons.com)
09:37AM	Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. What It Means for the Stock. (Barrons.com)
09:17AM	Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises. (Barrons.com)
02:03AM	Connecting Excellence Group appoints chief performance and growth officer (Proactive)
Mar-27-26 11:40AM	Consecutive approvals of Opdivo for Hodgkins lymphoma to boost sales growth (Clinical Trials Arena)
Mar-26-26 01:30AM	22 S&P 500 Stocks Yield More Than 5%. 6 That Are Worth Buying. (Barrons.com)
Mar-24-26 11:02AM	Pfizer CFO Dave Denton Highlights Firms Recent Oncology Milestones (NYSE)
10:39AM	Pfizer Reports 73% Lyme Vaccine Efficacy as Trial Results Complicate Outlook (GuruFocus.com)
10:00AM	Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts (Business Wire)
05:57AM	Immutrin raises $87M to advance drug for progressive heart disease (BioPharma Dive)
Mar-23-26 02:31PM	Pfizer-Valneva Lyme disease vaccine falls short as low cases skew results (Clinical Trials Arena)
01:00PM	Stocks Rise, Oil Falls as Trump Eases Iran Threats: Markets Wrap (Bloomberg)
12:46PM	Pfizer's Lyme Vaccine Shows Strong Efficacy, but Misses Mark in Study (The Wall Street Journal)
09:54AM	Mixed results for Lyme disease vaccine hit Valneva shares (AFP)
08:06AM	Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results (BioPharma Dive)
08:00AM	Telescope Innovations Announces Expansion of Consulting Role for Dr. Joel M. Hawkins, Industry Leader in Process Chemistry Automation (TMX Newsfile)
07:07AM	Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial (MarketWatch)
07:02AM	Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial (The Wall Street Journal)
06:45AM	Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial (Business Wire)
Mar-22-26 09:00PM	IP Group PLC (IPZYF) Full Year 2025 Earnings Call Highlights: Strong NAV Growth Amid Market ... (GuruFocus.com)
Mar-20-26 04:30PM	Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC (Business Wire)
Mar-19-26 09:47AM	ImmuPharma, Ilika, Coinsilium Group, IP Group, Team Internet Group - Small Cap Week in Review (Proactive)
07:37AM	Pfizer aims for wider use of PARP drug in prostate cancer with new data (BioPharma Dive)
07:30AM	The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients (Fortune)

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SAHNI PAYAL	Executive Vice President	Feb 25 '26	Option Exercise	33.82	56,888	1,923,952	82,816	Feb 27 06:35 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 25 '26	Option Exercise	33.82	122,907	4,156,715	282,186	Feb 27 06:35 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 25 '26	Option Exercise	33.82	17,558	593,812	29,744	Feb 27 06:35 PM
BOURLA ALBERT	Chairman & CEO	Feb 25 '26	Option Exercise	33.82	491,626	16,626,791	864,215	Feb 27 06:34 PM
Fonseca Lidia	Executive Vice President	Feb 25 '26	Option Exercise	33.82	56,888	1,923,952	101,579	Feb 27 06:34 PM
McDermott Michael	Executive Vice President	Feb 25 '26	Option Exercise	33.82	37,925	1,282,624	114,534	Feb 27 06:34 PM
Dolsten Mikael	Former Officer	May 23 '25	Proposed Sale	23.09	59,781	1,380,632		May 23 10:54 AM

ILMN

Illumina Inc

TEM

Tempus AI Inc

PFE

Pfizer Inc

Upgrade your Finviz experience